BIVI today
$1.21-$0.05 (-3.97%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourExpanding
1 hourStrong Bearish
15 minStrong Bearish
5 minSymmetric Triangle
Daily trend turns up above $3.79
Key levels
Resistance$1.69
Resistance$1.40
Support$1.10
Latest news & SEC filings
ProductBioVie reports fresh biomarker results from Bezisterim long COVID study
All BIVI news →About BioVie
BioVie develops experimental medicines for brain and nerve disorders as well as severe liver disease. Its main candidate, bezisterim, is under study for Parkinson's disease, Alzheimer's disease, and long COVID, while BIV201, a liquid terlipressin given by continuous infusion, aims at cirrhosis complications including ascites. The company works mainly in the United States and holds patents in North America, Europe, and Asia.
Based on the company's 10-K filed Aug 13, 2026.
Nasdaq · Healthcare
BIOVIE INC. (BIVI)
What Is the Price Target for BIVI?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is BIVI a Buy or Sell Right Now?
Thesis
- •Smart money flows are positive — institutional and insider activity shows net buying.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for BIVI.
Start Free Trial →Is BIVI Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B
Fair Value
$3.45
10
Moat Score
NONE
1/9
Piotroski Score
-39.9
Altman Z-Score
What Is Smart Money Doing with BIVI?
Insider Signal
BUYING
4 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Palumbo Joseph M | officer | Buy | 4,843 | $10K | Aug 28, 2026 |
| Chappell Amy Suzon | director | Buy | 727 | $2K | Aug 28, 2026 |
| KIM JOANNE WENDY | officer | Buy | 2,500 | $5K | Aug 28, 2026 |
| DO CUONG V | director officer | Buy | 15,210 | $32K | Aug 27, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →BIVI Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
74.83%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for BIVI
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for BIVI, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 14:58:37 | $1.18 | 1,889 | $$2K | SELL |
| 14:58:37 | $1.20 | 4,995 | $$6K | SELL |
| 14:42:19 | $1.21 | 1,200 | $$1K | SELL |
| 14:40:44 | $1.21 | 2,502 | $$3K | SELL |
| 14:32:54 | $1.22 | 3,000 | $$4K | BUY |
5 dark pool trades shown · $$16K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for BIOVIE INC. (BIVI) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →BIVI — frequently asked questions
What is BIVI stock price today?
BIOVIE INC. (BIVI) is at $1.21, down 3.97% (-$0.05) at the Nov 12, 2026 close.
Why is BIVI stock moving today?
Latest BIVI news — Nov 10, 2026: BioVie reports fresh biomarker results from Bezisterim long COVID study
What do analysts rate BIVI?
Analyst ratings for BIVI: 2 Buy, 0 Hold, 0 Sell — consensus Strong Buy.
Did BIVI beat earnings?
BIVI last reported on Aug 12, 2026: EPS -$0.70 vs -$0.52 expected — a miss of 34.6%.
Does BIVI pay a dividend?
BIVI does not currently pay a dividend.
What are BIVI support and resistance levels?
Support: $1.10. Resistance: $1.40, $1.69, $1.91.
What are insiders doing with BIVI?
Insider activity: BUYING, 4 buys and 0 sells in the last 90 days.
What is the latest news on BIVI?
Nov 10, 2026: BioVie reports fresh biomarker results from Bezisterim long COVID study